Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

(2010) Paola Sperone et al.   ENDOCRINE-RELATED CANCER

Transcatheter Arterial Chemoembolization for Liver Metastases in Patients with Adrenocortical Carcinoma

(2010) Julien Cazejust et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

(2009) Sebastian Wortmann et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Emerging drugs for adrenocortical carcinoma

(2008) Alfredo Berruti et al.   EXPERT OPINION ON EMERGING DRUGS

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

A hypoxic twist in metastasis

(2008) Héctor Peinado et al.   NATURE CELL BIOLOGY

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY